

Haematologica
HAEMATOL/2016/159343
Version 3

Minimal residual disease prior to allogeneic hematopoietic cell
transplantation in acute myeloid leukemia: a meta-analysis

Sarah A. Buckley, Brent L. Wood, Megan Othus, Christopher S.
Hourigan, Celalettin Ustun, Michael A. Linden, Todd E. DeFor, Michele
Malagola, Chloe Anthias, Veronika Valkova, Christopher G. Kanakry,
Bernd Gruhn, Francesco Buccisano, Beth Devine, and Roland B.
Walter

Disclosures: C.S.H. receives research funding from SELLAS Life Sciences Group AG.
M.A.L. is a consultant to Bristol Myers Squibb and receives royalties from Cell Signaling
Technology.

Contributions: S.A.B. and R.B.W. were responsible for the concept of this meta-analysis
and contributed to the literature search, data collection quality assessment, data analysis
and interpretation, and writing of the manuscript. B.L.W. provided guidance on the risk of
bias assessment, analyzed and interpreted data, and revised the manuscript. M.O. and
B.D. provided guidance on statistical methodology, analyzed and interpreted data, and
revised the manuscript. C.S.H, C.U., M.A.L., T.E.D., M.M., C.A., V.V., C.G.K., B.G., and
F.B. contributed data, analyzed and interpreted data, and revised the manuscript.